NeuroOne Medical Technologies Corporation
NMTCHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, NeuroOne Medical Technologies Corporation (NMTC) is listed under Medical Devices. The company carries a $17.8M market cap, placing it firmly in the micro-cap category. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
Market Cap
$17.8M
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
-7.32
EPS (TTM)
$-0.83
EPS (Fwd)
$-0.28
ROE
-204.4%
ROA
-71.7%
Cash
$2.8M
Total Debt
$206,973
Free CF
-$5.4M
52W Change
-66.8%
Annual Financials
Cash vs Debt
Where NMTC stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NMTC finished 43.75% below its 150-day moving average ($4.32) and 45.15% below its 200-day moving average ($4.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NMTC overbought or oversold?
At the July 15, 2026 close, NMTC's RSI(14) was 21.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.8M in cash comfortably exceeding the $207K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$5.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -204.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $171K (2022) to $9.1M (2025), reflecting a 5215% increase over the period.
The relatively low beta of 0.53 suggests NMTC is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence NeuroOne Medical Technologies Corporation's trajectory.